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Abstract
Background: To initiate infection, Bacillus anthracis needs to overcome the host innate immune system. Anthrax toxin, a
major virulence factor of B. anthracis, impairs both the innate and adaptive immune systems and is important in the
establishment of anthrax infections.
Methodology/Principal Findings: To measure the ability of anthrax toxin to target immune cells, studies were performed
using a fusion of the anthrax toxin lethal factor (LF) N-terminal domain (LFn, aa 1–254) with b-lactamase (LFnBLA). This
protein reports on the ability of the anthrax toxin protective antigen (PA) to mediate LF delivery into cells. Primary immune
cells prepared from mouse spleens were used in conjunction with flow cytometry to assess cleavage and resulting FRET
disruption of a fluorescent b-lactamase substrate, CCF2/AM. In spleen cell suspensions, the macrophages, dendritic cells,
and B cells showed about 75% FRET disruption of CCF2/AM due to cleavage by the PA–delivered LFnBLA. LFnBLA delivery
into CD4+ and CD8+ T cells was lower, with 40% FRET disruption. When the analyses were done on purified samples of
individual cell types, similar results were obtained, with T cells again having lower LFnBLA delivery than macrophages,
dendritic cells, and B cells. Relative expression levels of the toxin receptors CMG2 and TEM8 on these cells were determined
by real-time PCR. Expression of CMG2 was about 1.5-fold higher in CD8+ cells than in CD4+ and B cells, and 2.5-fold higher
than in macrophages.
Conclusions/Significance: Anthrax toxin entry and activity differs among immune cells. Macrophages, dendritic cells, and B
cells displayed higher LFnBLA activity than CD4+ and CD8+ T cells in both spleen cell suspension and the purified samples
of individual cell types. Expression of anthrax toxin receptor CMG2 is higher in CD4+ and CD8+ T cells, which is not
correlated to the intracellular LFnBLA activity.
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Introduction
Bacillus anthracis is a gram-positive, spore forming bacterial
pathogen. Anthrax infection occurs when dormant spores enter an
animal and germinate, resulting in growth and dissemination of
vegetative bacteria. Anthrax infections can occur in three forms,
inhalational, gastrointestinal, and cutaneous, depending on the
route by which spores enter the host [1]. Inhalational anthrax is
the most severe form of infection, often leading to mortality unless
rapidly diagnosed and treated.
After spore invasion, innate immunity is the front line of defense
against infection. Early histopathological studies showed that in
inhalational anthrax, spores in the lungs are efficiently taken up by
phagocytic cells and transported to the regional lymph nodes [2].
There are contradictory reports on the fate of spores in
macrophages. Some studies suggested that macrophages act as
Trojan horses, allowing spores to germinate and grow into vege-
tativecells [3,4].Otherresearchers haveshown that phagocytic cells
can take up and kill spores or the newly germinated vegetative cells
[5–7]. Mice depleted of macrophages are more susceptible to
anthrax infection [8], supporting a protective role for these cells.
Dendritic cells (DCs) are also capable of taking up spores [9] and
lung DCs can transport spores to regional lymph nodes [10].
Human neutrophils can also engulf and effectively kill intracellular
spores [11]. Neutrophil depletion in mice, however, does not alter
the infection process [8].
To initiate infection, B. anthracis produces virulence factors to
counter the host immune system. Anthrax toxin is an important
virulence factor in the pathogenesis of anthrax. This three-part
toxin consists of protective antigen (PA), edema factor (EF) and
lethal factor (LF) [12]. PA (83 kDa) first binds to its cellular
receptors, CMG2 and/or TEM8, and then furin or furin-like
proteases cleave PA and release the N-terminal 20-kDa fragment
[13–17]. The resulting 63-kDa species (PA63) assembles into an
oligomeric complex having binding sites for LF and EF. After
assembly of PA63 bound to EF (called edema toxin, ET) or LF
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endocytosis. The low pH in endosomes triggers a conformational
change in the complex which in turn allows LF/EF translocation
to the cytosol of mammalian cells (for review see [18]). LF is a
metalloproteinase that cleaves and inactivates the mitogen-
activated protein kinase kinases (MEKs) 1–4, 6 and 7, and thereby
blocks three pivotal mitogen-activated protein kinase (MAPK)
pathways [19–21]. By targeting these important cell signaling
pathways, LT suppresses cellular components of innate immunity.
LT causes macrophages necrosis and apoptosis as well as blocking
the production of pro-inflammatory cytokines and chemokines.
LT also targets DCs, which bridge innate immunity and adaptive
immunity. LT not only induces apoptosis of DCs so as to
physically remove them from the system, but also blocks
maturation of DCs so as to interrupt their ability to activate B
cells and T cells [22]. The adaptive immune system is also attacked
directed by LT, by blocking B cell proliferation and antibody
production as well as T cell activation and proliferation [23]. EF is
a calmodulin-dependent adenylate cyclase that elevates intracel-
lular cAMP levels, thereby activating cAMP-dependent protein
kinases and perturbing many cellular systems [24].
The small amounts of anthrax toxin that enter cells cannot
easily be detected by direct visualization. Thus our lab previously
developed a system utilizing a fusion protein, LFnBLA, consisting
of the N-terminal region of LF (LFn) and b-lactamase (BLA),
which together with the substrate coumarin cephalosporin
fluorescein acetoxymethyl ester (CCF2/AM), allows imaging of
the toxin delivery into cells [25]. CCF2/AM is a membrane
permeable cephalosporin derivative that has fluorophores attached
to opposite sides of the b-lactam ring of cephalosporin, resulting in
fluorescence resonance energy transfer (FRET). The molecule
normally shows an emission at 520 nm (green fluorescence) when
excited at 409 nm. Cleavage of CCF2/AM by b-lactamase
releases one fluorophore, disrupting the FRET, and shifting the
emission to 440 nm (blue fluorescence). In this report we
employed the LFnBLA system to assess the entry of LF into
primary immune cells isolated from mouse spleens by measuring
FRET disruption, allowing us to make predictions of the relative
amounts of anthrax toxin entering various immune cells.
Results
Microscopic visualization of LFnBLA activity in spleen
cells
The spleen is an immunologic filter of the blood and contains
macrophages, DCs, and B and T lymphocytes. Therefore we
used mouse spleens as our source of immune cells. Although the
b-lactamase activity of LFnBLA could be easily visualized in cell
lines such as CHO cells and HeLa cells [25] (and data not shown),
it was difficult to see significant differences between LFnBLA + PA
treated and untreated spleen cells by microscopy after CCF2/AM
staining (Figure 1). A Victor fluorescence reader (Perkin Elmer,
Shelton, CT) also did not detect substantial differences in treated
and untreated spleen cells (data not shown).
Flow cytometric analyses of LFnBLA activity in spleen
immune cells
We next examined the more sensitive flow cytometric method
for its ability to detect LFnBLA activity. Single spleen cell
suspensions were treated with LFnBLA + PA and stained with
CCF2/AM before they were subjected to flow cytometry. We
found that 54.6+/2 10.0% of spleen cells underwent FRET
disruption after 1 h of LFnBLA + PA treatment, compared to the
untreated control cells or those treated with LFnBLA alone
(Figure 2B–2D). To further study the response of each type of
immune cell to LFnBLA + PA treatment, cells were labeled with
APC or PE-Cy7 conjugated antibodies specific for cell type-
specific surface markers following CCF2/AM staining, so the
FRET disruption of individual cell populations in the spleen cell
suspension could be distinguished. DCs, macrophages and B cells
showed about 75 to 80% FRET disruption, significantly greater
than what was observed for both CD4+ and CD8+ T cells. CD8+
cells showed about 52% FRET disruption, and CD4+ cells had
42% FRET disruption (the lowest compared to the other four
types of cells tested) (Figure 2E).
Flow cytometric analyses of LFnBLA activity in purified
cell populations
To test the activity of the LFnBLA fusion protein in purified
immune cells, Miltyni microbeads were used to separate
macrophages, B cells, CD4 cells and CD8 cells from the single
spleen cell suspensions before LFnBLA/PA treatment. In purified
immune cells, macrophages and B cells displayed about 65% and
80% of FRET disruption, respectively (Figure 3), higher than the
activity detected in CD4+ and CD8+ T cells (32% and 25% of
FRET disruption, respectively). This is similar to what was
observed with the mixed spleen cell suspension. CD8+ cells,
however, responded significantly higher than CD4+ cells in the
mixed population (Figure 2), but responded similarly to CD4+ cells
after purification. DCs indicated 86% FRET disruption, similar to
macrophages and B cells (data not shown).
Figure 1. Fluorescence imaging of LFnBLA activity in spleen cells. Single cell suspensions were attached to polylysine-treated plates and
then subjected to treatment with LFnBLA + PA followed by CCF2/AM staining. (A) Phase contrast photo showing the single cells in the spleen cell
suspension. (B) Spleen cells treated with LFnBLA alone before CCF2/AM staining. (C) Spleen cells treated with LFnBLA + PA followed by CCF2/AM
staining. The arrows point to cells with significant FRET disruption.
doi:10.1371/journal.pone.0007946.g001
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To test if the enzymatic activity of the LFnBLA fusion protein in
the cytosol was proportional to PA receptor levels expressed on
immune cells, RT-PCR was performed to assess TEM8 and
CMG2 levels in each cell population. Expression levels of TEM8
in all immune cells was much lower than that of CMG2, which
recent evidence suggests is the more important and physiologically
relevant receptor in mice [17]. Expression of CMG2 in CD8+ cells
was about 1.5-fold higher than that in CD4+ and B cells, and
2.5-fold higher than in macrophages (Figure 4). DCs had the
lowest CMG2 expression among all the immune cells isolated from
mouse spleen, at about half the level in macrophages.
Discussion
Anthrax toxin is important in the establishment of anthrax
infection. Both LT and ET are produced very early after spore
germination [26]. Toxin impairment of the host immune system
allows vegetative bacteria to replicate, disseminate and eventually
kill the host. It is important to determine the relative activities of
the toxins in various immune cell types in order to better
understand the interaction of this pathogen and the immune
system. Direct measurement of the LF and EF proteins in cells is
technically challenging, because receptor levels on most cell types
average 20,000/cell [27]. Because the heptameric PA channel
probably uses 7 receptor molecules to internalize at most 3 LF or
EF molecules, and the process is unlikely to be error-free, it can be
expected that cells on average internalize fewer than 10,000
molecules of LF or EF [25]. Furthermore, although the anthrax
toxin receptors CMG2 and TEM8 are widely expressed in various
animal tissues, the mouse spleen has a lower amount of receptors
compared to the heart and liver [17]. While it may be possible to
measure the consequences of LF and EF internalization (MEK
cleavage and cAMP increases), these measurements each have
Figure 2. Flow cytometric analysis of LFnBLA activity in spleen cells. Spleen cells were treated with LFnBLA +PA and then stained with CCF2/AM. Cell
specific markers were used to differentiate each immune cell type after CCF2/AM staining. (A) Unstained spleen cells showing autofluorescence. (B) Untreated
spleen cells stained with CCF2/AM. (C) Spleen cells treated with LFnBLA alone followed by CCF2/AM staining. (D) Spleen cells treated with LFnBLA + PA
followed by CCF2/AM staining. (E) Response of various types of immune cells to LFnBLA +PAtreatment in aspleen cell suspension. Experiments were repeated
t h r e et i m e s ,e a c ht i m ew i t had i f f e r e n t mouse spleen, with error bars showing 61 SD (standard deviation). (P=0.008 comparing macrophages and CD8 cells).
doi:10.1371/journal.pone.0007946.g002
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fusion of the N-terminal domain of LF with b-lactamase to assess
the ability of various cell types to internalize LF. b-lactamase
fusions have been widely used as reporters to study bacterial and
viral internalization by host cells [28,29], and are also an effective
tool to study the entry of bacterial effector proteins [30,31]. The
LFnBLA fusion protein presented in this work provides a useful
tool to indirectly assess the entry/activity of toxin in various cells.
In this study, we titrated the concentrations of LFnBLA and PA
in preliminary experiments and chose the lowest concentrations
that consistently produced high FRET disruption. The selected
concentration of 1 ug/ml PA (12 nM) is near the concentration
needed to saturate the CMG2 and TEM8 receptors, which have
apparent Kd values of about 1 and 10 nM, respectively [17].
These PA and LF concentrations were used because the objective
was to assess the capacity of each cell type to internalize toxin, and
it was therefore desirable to saturate the uptake system. These
concentrations are probably not present in the early stages of an
infection, but concentrations .200 ng/ml have been reported to
occur late during an infection [32,33].
To successfully establish an infection, B. anthracis needs to
combat the host immune system. The innate response mounts a
rapid defense after spores enter the host. Macrophages and DCs
sequester the spores by phagocytosis. Previous research indicated
that most intracellular spores germinate inside macrophages
within the first hour [3,7], but there are contradictory results on
the fate of the germinated spores. Some reports show that spores
grow into vegetative bacteria and escape from the macrophages,
while other research suggests that macrophages efficiently kill
germinated spores [4,6,7,34]. DCs have been shown to be capable
of transporting spores to regional lymph nodes [9,10]. For the
spores to initiate infection, they need to kill the phagocytic cells
that sequester them soon after germination. Escape from
phagocytic cells probably takes place before the adaptive immune
response is initiated. Anthrax toxin is synthesized in the log phase
after spores germinate and grow as vegetative cells [26,35] and its
accumulation following the germination of a few initial spores is
required for other spores to escape phagocytic cells [36]. It would
be consistent with this view if the DCs and macrophages were
among the most toxin-sensitive immune cells, as they are the front
line of the host defense, and sequestered spores escaping from
these cells at the correct time is the most important step early in
anthrax infection. In fact, our results show that macrophages, DCs
and B cells have higher b-lactamase activity than T cells in both
purified cells and mixed cell suspension, suggesting that these three
cell types are more sensitive to anthrax LT.
In addition to countering innate immunity, B. anthracis also
appears to target components of adaptive immunity through
attacking B cells and antigen-presenting cells. DCs are the major
antigen presenting cells that bridge the innate and adaptive
immune systems [37]. DCs take up microbial pathogens, process
them and display a specific portion of the pathogen on the surface
to present to T cells. LT decreases DCs’ ability to prime naı ¨ve T
cells [38]. Since T cells can only recognize processed antigen in the
context of the MHC, it may be that B. anthracis has evolved to
efficiently impair the adaptive immunity by attacking DCs, which
are fewer than 3% of the white blood cells in the spleen/blood,
rather than attacking T cells directly.
The differences in LF activity towards various immune cell types
observed in this work are not likely to be due only to differences in
receptor levels. CMG2 binds to PA with up to 10-fold higher
affinity than TEM8, and is the principal receptor contributing to
in vivo toxicity of anthrax toxin [17]. We show here that
expression of CMG2 is much higher than TEM8 in all types of the
spleen immune cells tested, and the expression levels of CMG2 do
not correlate with the intracellular b-lactamase activity observed.
Macrophages, DCs and B cells, which exhibit the highest
enzymatic activity, actually have lower amounts of receptor
expressed. The internalization of LFnBLA (and therefore LF) to
the cytosol involves a number of steps following receptor binding,
including furin cleavage of PA, migration to lipid rafts,
endocytosis, trafficking through endocytic vesicles, and transloca-
tion across membranes [39]. Each of these processes could differ in
efficiency between the cell types studied here. Thus, it is not
surprising that no correlation was observed between the expres-
sion levels of the major receptor CMG2 and the intracellular
b-lactamase activity.
The use of LFnBLA for monitoring LF activity is not only
important in studying disease initiation, but may facilitate cancer
treatment in the future. Anthrax toxin-based variants have been
shown to have an antitumor effect for several types of tumor, such
as melanoma, fibrosarcomas and lung carcinoma [40]. The uptake
Figure 3. Flow cytometric analysis of LFnBLA activity in each
type of immune cell from mouse spleens. Spleen cells were purified
by magnetic beads and each type of cell was treated with LFnBLA + PA
before CCF2/AM staining. Experiments were repeated three times.
(P=0.026 comparing macrophages and CD4 cells, P=0.011 comparing B
cells and CD4 cells, and P=0.049 between CD4 and CD8 cells).
doi:10.1371/journal.pone.0007946.g003
Figure 4. Real-time PCR result showing the relative expression
levels of anthrax toxin receptors in immune cells. CMG2 and
TEM8 expression levels in immune cells isolated from mouse spleens
were normalized to those of b-actin in the same cell type. The data are
reported as mean of amounts relative to b-actin 61 SD.
doi:10.1371/journal.pone.0007946.g004
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of treatment. The method described here can assess the potency of
toxin treatments against cancer cells [41,42] and may also
potentially be adapted for use in animal studies in the future.
Materials and Methods
Bacterial strains and protein purification
The LFnBLA fusion protein was purified from Escherichia coli
BL21(DE3) [25] and PA was purified from B. anthracis as described
previously [43].
Spleen cell isolation
Mouse spleens were obtained from C57BL/6J mice (Jackson
Laboratory, Bar Harbor, ME). Single cell suspensions were
obtained by mechanical disruption and passage through a 70-mm
cell strainer (BD Biosciences, San Jose, CA). Red blood cells were
lysed by incubating the single cell suspension in 0.83% KHCO3-
0.1%NH4Cl-0.01 MEDTA(pH7.4),ahypotonicbuffer,onicefor
10 min. After three washes with PBS (Invitrogen, Carlsbad, CA)
cells were resuspended in DMEM (Dulbecco’s Modified Eagle
Medium without phenol red, Invitrogen) and counted using a
Cellometer (Nexcelom, Lawrence, MA).
Spleen cell labeling and separation
Single spleen cell suspensions (10
8 cells) from multiple mouse
spleens were incubated in 1 ml blocking buffer (PBS, pH 7.4, 0.5%
BSA, 2 mM EDTA). Magnetic beads conjugated with the cell-type
specific markers CD11b, CD4 (L3T4), B220, or CD8 (Ly-2)
(Miltenyi, Auburn, CA) were used to purify individual cell types
using the protocols suggested by the manufacturer. Sorted cells
were subjected to fluorescent labeling to check for purity by flow
cytometry. Macrophages were .80% pure, while purities of other
cell types were .90%.
Microscopic visualization of LFnBLA activity
Tissue culture-treated, clear-bottom black-wall 96-well plates
(Corning Inc., Corning, NY) were treated for 15 min with 0.1 mg/
ml polylysine (50 ml/well) (Sigma Chemical Co., St. Louis, MO)
prepared in PBS. After removal of polylysine, wells were washed
with 100 ml PBS three times. Spleen cells were added (10
5/well,
suspended in DMEM + 2% FBS) and then treated with LFnBLA
(2 mg/ml) plus PA (1 mg/ml) at 37uC for1 h.Cells were thenwashed
three times with PBS before adding Alternative Substrate Loading
Solution (6 ml solution A containing CCF2/AM, 60 mls o l u t i o nB ,
925 ml solution C, and 2 mM probenecid). CCF2/AM and loading
solution components were purchased from Invitrogen and proben-
ecid was purchased from MP Biomedicals Inc. (Solon, OH). Cells
were incubated with CCF2/AM at room temperature, avoiding
light, for 4 h. Microscopy was performed using a Nikon TE2000-U
Eclipse fluorescence microscope with BV-2A filter (excitation at
409 nm and emission at 447/520 nm) (Nikon, Melville, NY).
Flow cytometric analysis of LFnBLA activity
Spleen cells were resuspended at 10
6 per 0.5 ml in DMEM +
2% FBS, and treated with LFnBLA (2 mg/ml) plus PA (1 mg/ml)
at 37uC for 1 h. After three washes with PBS, the cells were
resuspended in 500 ml DMEM, and 100 ml modified loading
solution (6 ml solution A, 60 ml solution B, 904 ml PBS and
0.1 mM probenecid) was added to cells. After 4 h of incubation at
room temperature, cells were washed three times with PBS/
probenecid (PBS supplemented with 0.1 mM probenecid). Cells
were then resuspended in PBS/probenecid before flow cytometric
analyses. To examine LFnBLA activity in individual cell types,
after the CCF2/AM incubation and washes, spleen cell suspen-
sions were stained with APC-anti-mouse CD11b, PE-Cy7-anti-
mouse CD11c, PE-Cy7-anti-mouse B220, APC-anti-mouse CD4,
or PE-Cy7-CD8a (BD Pharmingen, San Jose, CA). Antibodies
were titrated to identify optimum concentrations. Staining was
performed in PBS/probenecid with the optimized dilution of the
labeled antibodies at 4uC for 20 min, followed by three washes
with PBS/probenecid. The BD LSRII flow cytometer (BD
Biosciences, San Jose, CA) was used to detect CCF2/AM FRET
disruption by assessing emission at 440/40 nm for blue light and
525/50 nm for green light using excitation at 405 nm. The same
method was used to treat the purified individual immune cells.
Briefly, cells were resuspended with DMEM + 2% FBS after
purification by Miltenyi magnetic beads, and treated with the
same concentration of LFnBLA/PA. After three washes with PBS,
the cells were stained with CCF2/AM with modified substrate
loading solution and subjected to flow cytometric analysis. Flowjo
software (TreeStar Inc., Ashland, OR) was used for data analysis.
Real-time PCR
Total RNA isolated from purified mouse spleen immune cell
populations using Trizol (Invitrogen) was subjected to reverse
transcription to generate cDNA with the SuperScript II Reverse
Transcriptase kit (Invitrogen). Real-time PCR analyses were
carried out using the Applied Biosystems 7000 sequence detection
system and the TaqMan gene expression master mix (Applied
Biosystems, Foster City, CA). Primers for detection of CMG2 (Cat.
No. Mm01196014_g1), TEM8 (Mm00712952_m1), and b-actin
(Mm00607939_s1) were purchased from Applied Biosystems.
TEM8 and CMG2 expression levels are presented as amounts
relative to those of b-actin in each cell type.
Statistical analysis
Student t-test analyses were performed using Graphpad Prism
version 5.00 for Windows (GraphPad Software, San Diego
California USA, www.graphpad.com).
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